|
![]() |
|
|
Omnicef: profile and news
Medicis Announces FDA Approval of SOLODYN -- minocycline HCl, USP ... May 8, 2006 Medicis Reports First Quarter 2006 Financial Results May 9, 2006 Abbott Reports First Quarter Results Led by Strong Medical ... Apr 19, 2006 Other information Indication For the treatment of the following infections (respiratory, skin, soft tissue,ENT) caused by; H.influenzae (including b-lactamase producing strains), H.parainfluenzae (including b-lactamase producing strains), S. pneumoniae (penicillin-susceptible strains Pharmacology Not Available Mechanism Of Action Not Available Drug Category Anti-Infectives; ATC:J01DD15 Brand Names/Synonyms Cefdinir; Cefdinir [Usan:Inn]; Cefdinirum [Inn-Latin]; Cefdinyl; Cefdirnir; Omnicef Dosage Forms Not Available Absorption Not Available Interactions -->Interactions for Cefdinir: Antacids (aluminum- or magnesium-containing) Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox® TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%. Time to reach Cmax is also prolonged by 1 hour. There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir. If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid. Probenecid As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life. Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement. The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied. Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics. Therefore, OMNICEF for Oral Suspension can be administered with iron-fortified infant formula. There have been rare reports of reddish stools in patients who have received cefdinir in Japan. The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract. Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide. The administration of cefdinir may result in a false-positive reaction for glucose in urine using Clinitest®, Benedictís solution, or Fehling's solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix® or Tes-Tape®) be used. Cephalosporins are known to occasionally induce a positive direct Coombsí test. Chemical IUPAC Name 8-[2-(2-amino-1,3-thiazol-4-yl)-1-hydroxy-2-nitroso-ethenyl]amino-4-ethenyl-7-oxo-2-thia-6-azabicyclo[4.2.0]oct-4-ene-5-carboxylicacid Chemical Formula C14H13N5O5S2 Half Life 1.7 +/- 0.6 hours Drug Type Approved Drug # Accession No APRD00644 CAS Registry Number 91832-40-5 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |